(secondQuint)Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort Turbuhaler on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD.

 This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.

6 1/2g and 160/9.

6 1/2g) compared to FF MDI 9.

6 1/2g, BD MDI 320 1/2g, and open-label Symbicort(R) TBH (200/6 1/2g) administered BID.

 Subjects will undergo a 1- to 4-week Screening Period.

 Subjects who successfully complete the Screening Period will be to one of the following five treatment groups:BFF MDI 320/9.

6 1/2g BID (N=660), BFF MDI 160/9.

6 1/2g BID, FF MDI 9.

6 1/2g BID, BD MDI 320 1/2g BID, Symbicort(R), TBH 400/12 1/2g BID.

 Following randomization, subjects will enter the Treatment Period and undergo additional treatment visits over 24 weeks.

.

 Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort Turbuhaler on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD@highlight

This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung function study with BFF MDI (320/9.

6 1/2g and 160/9.

6 1/2g) compared to FF MDI 9.

6 1/2g, BD MDI 320 1/2g, and open-label Symbicort(R) TBH (200/6 1/2g) administered BID.

